JP2020534030A - トランスグルタミナーゼコンジュゲーション方法およびリンカー - Google Patents

トランスグルタミナーゼコンジュゲーション方法およびリンカー Download PDF

Info

Publication number
JP2020534030A
JP2020534030A JP2020537053A JP2020537053A JP2020534030A JP 2020534030 A JP2020534030 A JP 2020534030A JP 2020537053 A JP2020537053 A JP 2020537053A JP 2020537053 A JP2020537053 A JP 2020537053A JP 2020534030 A JP2020534030 A JP 2020534030A
Authority
JP
Japan
Prior art keywords
linker
antibody
payload
amino acid
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020537053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534030A5 (https=
Inventor
スピッヒャー，フィリップ
シブリ，ロジャー
ベーエ，マーティン
ヴェルミュラー，ジョリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scherrer Paul Institut
Original Assignee
Scherrer Paul Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800878.9A external-priority patent/GB201800878D0/en
Application filed by Scherrer Paul Institut filed Critical Scherrer Paul Institut
Publication of JP2020534030A publication Critical patent/JP2020534030A/ja
Publication of JP2020534030A5 publication Critical patent/JP2020534030A5/ja
Priority to JP2024034922A priority Critical patent/JP2024081670A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020537053A 2017-09-19 2018-09-19 トランスグルタミナーゼコンジュゲーション方法およびリンカー Pending JP2020534030A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034922A JP2024081670A (ja) 2017-09-19 2024-03-07 トランスグルタミナーゼコンジュゲーション方法およびリンカー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17191825 2017-09-19
EP17191825.3 2017-09-19
GB1800878.9 2018-01-19
GBGB1800878.9A GB201800878D0 (en) 2018-01-19 2018-01-19 Transglutaminase conjugation method and linker
PCT/EP2018/075350 WO2019057772A1 (en) 2017-09-19 2018-09-19 METHOD FOR CONJUGATING TRANSGLUTAMINASE AND BINDING SEQUENCE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034922A Division JP2024081670A (ja) 2017-09-19 2024-03-07 トランスグルタミナーゼコンジュゲーション方法およびリンカー

Publications (2)

Publication Number Publication Date
JP2020534030A true JP2020534030A (ja) 2020-11-26
JP2020534030A5 JP2020534030A5 (https=) 2021-07-26

Family

ID=63678617

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020537053A Pending JP2020534030A (ja) 2017-09-19 2018-09-19 トランスグルタミナーゼコンジュゲーション方法およびリンカー
JP2024034922A Pending JP2024081670A (ja) 2017-09-19 2024-03-07 トランスグルタミナーゼコンジュゲーション方法およびリンカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034922A Pending JP2024081670A (ja) 2017-09-19 2024-03-07 トランスグルタミナーゼコンジュゲーション方法およびリンカー

Country Status (10)

Country Link
US (3) US12128110B2 (https=)
EP (1) EP3684419A1 (https=)
JP (2) JP2020534030A (https=)
KR (1) KR102697329B1 (https=)
CN (1) CN111163809B (https=)
AU (1) AU2018337671B2 (https=)
CA (2) CA3177215A1 (https=)
MX (1) MX2020002995A (https=)
NZ (1) NZ762376A (https=)
WO (1) WO2019057772A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513804A (ja) * 2020-02-13 2023-04-03 オラノ・メッド 抗体の部位特異的修飾のための方法
WO2023054706A1 (ja) * 2021-09-30 2023-04-06 味の素株式会社 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
JP2023546493A (ja) * 2020-10-25 2023-11-02 アラリス バイオテック アーゲー 抗体－リンカーコンジュゲートを生成するための手段および方法
JP2024501140A (ja) * 2020-11-30 2024-01-11 アンビション ソチエタ レスポンサビリタ リミタータ 抗体断片で修飾され、且つ細胞障害性物質がロードされた多重特異性ヒトアルブミンナノ粒子
WO2024210154A1 (ja) * 2023-04-04 2024-10-10 味の素株式会社 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
AU2021275632A1 (en) 2020-05-20 2023-02-02 Janssen Biotech, Inc. Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
JP7787101B2 (ja) * 2020-05-20 2025-12-16 ヤンセン バイオテツク，インコーポレーテツド グリコシル化Ｆｃドメインを含むタンパク質の部位特異的コンジュゲーションのための方法
KR20230069211A (ko) * 2020-09-18 2023-05-18 아라리스 바이오테크 아게 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법
CN116801910A (zh) * 2020-10-25 2023-09-22 阿拉里斯生物技术股份公司 生产抗体-接头偶联物的手段和方法
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
WO2023281480A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
EP4366781A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
JP2025505835A (ja) * 2022-02-22 2025-02-28 アーデーセー セラピューティクス ソシエテ アノニム トリミングされたｎ－グリカンを含むｆｃ領域でのトランスグルタミナーゼを伴うコンジュゲーション方法
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
US20250179210A1 (en) 2022-03-09 2025-06-05 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
US20250304927A1 (en) * 2022-05-20 2025-10-02 Curie Co. Inc. Pro-peptide variants for modulating activity of transglutaminases
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
CN121604979A (zh) 2023-05-23 2026-03-03 上海联进生物科技有限公司 包含效应分子的pd-l1和trop-2靶向缀合物及其用途
EP4673182A1 (en) * 2023-06-04 2026-01-07 Araris Biotech AG Dual payload antibody drug conjugates for the treatment of cancer
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2025242909A1 (en) 2024-05-24 2025-11-27 Paul Scherrer Institut CD30-targeting antibody-radioligand conjugates and their therapeutic use
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)
EP4684803A1 (en) 2024-07-25 2026-01-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof
WO2026069134A1 (en) 2024-09-26 2026-04-02 Bright Peak Therapeutics Ag Human therapy with il-18 immunocytokines
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
JP2014500866A (ja) * 2010-11-05 2014-01-16 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2016528183A (ja) * 2013-06-21 2016-09-15 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2016207090A2 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Site specific homogeneous with ksp inhibitors

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US5969516A (en) 1997-07-25 1999-10-19 Ntc, Inc. Electrical circuit interrupter device locator
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP1499885B1 (en) 2001-08-01 2009-10-21 Cellomics, Inc. Novel fusion proteins and assays for molecular binding
US6660510B2 (en) 2001-12-17 2003-12-09 Food Industry Research And Development Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom
EP2289942B1 (en) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
DK1599278T3 (da) 2003-01-17 2011-07-18 Danisco Fremgangsmåde til fremstilling af en hydroxysyreester
US7955814B2 (en) 2003-01-17 2011-06-07 Danisco A/S Method
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2008215422B2 (en) 2007-02-15 2011-07-14 Ajinomoto Co., Inc. Transglutaminase having disulfide bond introduced therein
US20100087371A1 (en) 2007-02-22 2010-04-08 Sean Hu Transglutaminase Variants with Improved Specificity
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
WO2009072004A2 (en) 2007-09-26 2009-06-11 Gemin X Pharmaceuticals Canada, Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
ES2784829T3 (es) 2009-04-08 2020-10-01 Faulstich Heinz Dr Componentes de unión a la superficie de células terapéuticas provistos de amatoxina diseñados para terapia de tumores
AU2010234335A1 (en) 2009-04-08 2011-10-13 Deutsches Krebsforschungszentrum Amatoxin-armed target-binding moieties for the treatment of cancer
WO2011077388A1 (en) 2009-12-22 2011-06-30 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
MX347954B (es) 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
WO2013049830A2 (en) * 2011-09-30 2013-04-04 The Washington University Tip-1 and grp-78 binding peptides and method of identifying peptide receptors
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
US10132799B2 (en) * 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2015015448A2 (en) 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
EP3055304A1 (en) 2013-10-09 2016-08-17 Eli Lilly and Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
US11376333B2 (en) 2013-12-23 2022-07-05 Covalab mTG substrates for covalent conjugation of compounds
PT3134127T (pt) 2014-04-25 2020-04-09 Rinat Neuroscience Corp Conjugados de anticorpo-fármaco com alta carga de fármaco
WO2015191883A1 (en) 2014-06-12 2015-12-17 Dophen Biomedical Homogenous antibody drug conjugates via enzymatic methods
PL3185908T3 (pl) 2014-08-28 2020-09-07 Pfizer Inc. Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek
WO2016100735A1 (en) 2014-12-19 2016-06-23 Roche Nimblegen, Inc. Microbial transglutaminases, substrates therefor and methods for the use thereof
EP3256166A1 (en) 2015-02-09 2017-12-20 NBE Therapeutics AG Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
JP2018510864A (ja) 2015-03-10 2018-04-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
ES2855998T3 (es) 2015-08-07 2021-09-27 Merck Patent Gmbh Etiqueta transglutamina para bioconjugación específica de sitio eficiente
TWI727380B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
UA124622C2 (uk) 2015-12-18 2021-10-20 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'юговані імуноглобуліни з c-кінцевим лізином
EP3272864A1 (en) 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
BR112019005964A2 (pt) * 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
MX2020004381A (es) 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
CA3128571A1 (en) 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
KR20230069211A (ko) 2020-09-18 2023-05-18 아라리스 바이오테크 아게 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법
KR20230096052A (ko) 2020-10-25 2023-06-29 아라리스 바이오테크 아게 항체-링커 접합체를 생성하기 위한 수단 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
JP2014500866A (ja) * 2010-11-05 2014-01-16 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2016528183A (ja) * 2013-06-21 2016-09-15 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2016207090A2 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Site specific homogeneous with ksp inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM, vol. 19, JPN6022020585, 2008, pages 271 - 278, ISSN: 0005006428 *
MOLECULAR CANCER, vol. 8, no. 25, JPN6023008884, 22 April 2009 (2009-04-22), ISSN: 0005006427 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513804A (ja) * 2020-02-13 2023-04-03 オラノ・メッド 抗体の部位特異的修飾のための方法
JP7671768B2 (ja) 2020-02-13 2025-05-02 オラノ・メッド 抗体の部位特異的修飾のための方法
JP2023546493A (ja) * 2020-10-25 2023-11-02 アラリス バイオテック アーゲー 抗体－リンカーコンジュゲートを生成するための手段および方法
JP7789396B2 (ja) 2020-10-25 2025-12-22 アラリス バイオテック アーゲー 抗体－リンカーコンジュゲートを生成するための手段および方法
JP2024501140A (ja) * 2020-11-30 2024-01-11 アンビション ソチエタ レスポンサビリタ リミタータ 抗体断片で修飾され、且つ細胞障害性物質がロードされた多重特異性ヒトアルブミンナノ粒子
WO2023054706A1 (ja) * 2021-09-30 2023-04-06 味の素株式会社 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
WO2024210154A1 (ja) * 2023-04-04 2024-10-10 味の素株式会社 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩

Also Published As

Publication number Publication date
AU2018337671B2 (en) 2021-03-04
NZ762376A (en) 2022-08-26
CA3075218A1 (en) 2019-03-28
AU2018337671A1 (en) 2020-03-26
US12128110B2 (en) 2024-10-29
CN111163809B (zh) 2024-07-02
CA3177215A1 (en) 2019-03-28
EP3684419A1 (en) 2020-07-29
CN111163809A (zh) 2020-05-15
KR20200057046A (ko) 2020-05-25
WO2019057772A1 (en) 2019-03-28
JP2024081670A (ja) 2024-06-18
MX2020002995A (es) 2020-07-22
KR102697329B1 (ko) 2024-08-23
US20240350656A1 (en) 2024-10-24
US20250161479A1 (en) 2025-05-22
US20210128743A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP2020534030A (ja) トランスグルタミナーゼコンジュゲーション方法およびリンカー
JP7629902B2 (ja) グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法
JP6310033B2 (ja) 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
EP3240573B1 (en) Enzymatic conjugation of polypeptides
EP4417627A1 (en) Recombinant fusion antibody, and antibody-drug conjugate and use thereof
JP7789396B2 (ja) 抗体－リンカーコンジュゲートを生成するための手段および方法
CN104781281A (zh) 包含抗体部分、穿过血脑屏障的多肽和细胞毒素的结合物
JP2020532523A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
US20240398972A1 (en) Methods for producing antibody-linker conjugates
US20230372525A1 (en) Transglutaminase conjugation method with amino acid-based linkers
TW202521160A (zh) 靶向傳遞至細胞之藥劑及方法
JP2026510850A (ja) リンカー及びそれを使用したカップリング薬物、抗体薬物複合体並びにその応用
WO2025206033A1 (ja) ｕＰＡＲ結合性ＨＬＨペプチド、ペプチド－薬物複合体および組成物
CN116801910A (zh) 生产抗体-接头偶联物的手段和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240517